Although cCRT followed by durvalumab maintenance is recommended, regardless of EGFR mutation status, for patients with stage III NSCLC, a recent exploratory post hoc subgroup analysis in a limited sample of 35 patients with EGFR mutations from the PACIFIC trial demonstrated similar PFS and OS between patients treated with durvalumab and placebo.25 This evidence concerns the gene EGFR and non-small cell lung carcinoma.